Aduhelm (aducanumab-avwa)

Member and Medication Information (required)	
Member ID:	Member Name:
DOB:	Weight:
Medication Name/ Strength:	Dose:
Directions for use:	

Provider Information (required)		
Name:	NPI:	Specialty:
Contact Person:	Office Phone:	Office Fax:

FAX FORM AND RELEVANT DOCUMENTATION INCLUDING: LABORATORY RESULTS, CHART NOTES and/or UPDATED PROVIDER LETTER TO 855-828-4992

Criteria for Approval (ALL of the following criteria must be met):

- ❑ The medication is prescribed by a board certified neurologist or geriatrician
- ❑ The member is between the ages of 50-85 years old
- ❑ The member has a diagnosis of Alzheimer's disease with mild dementia or mild cognitive impairment as evidenced by the following within the past 6 months:
  - ❑ Clinical Dementia Rating (CDR) global scale of ≤0.5 **AND**
  - ❑ Repeatable Battery for Assessment of Neuropsychological Status (RBANS) delayed memory index score ≤ 85 **AND**
  - ❑ Mini-Mental State Examination (MMSE) score of ≥ 24
- ❑ The request includes documentation of a brain MRI within the past year without evidence of the following:
  - ❑ Acute or sub-acute hemorrhage
  - ❑ Cortical infarct
  - ❑ >1 lacunar infarct
  - ❑ Prior microhemorrhage or prior subarachnoid microhemorrhage not due to underlying structural hemorrhage
  - ❑ Greater than 4 microhemorrhages
  - ❑ Superficial siderosis
  - ❑ History of diffuse white matter disease
- ❑ The request includes documentation showing presence of amyloid abnormalities as determined by positron emission tomography (PET) or lumbar puncture
- ❑ The member has documented 3-month trial and failure of the following:
  - ❑ Cholinesterase inhibitor (e.g. donepezil, rivastigmine)
  - ❑ Memantine
- ❑ The member has not experienced any of the following:
  - ❑ Alcohol or substance misuse in the past one year
  - ❑ Clinically significant or unstable psychiatric illness within the last 6 months
  - ❑ Contraindication to amyloid testing (e.g., PET or brain MRI)
  - ❑ History of other possible contributors to the symptoms of dementia (e.g., Huntington's Disease, HIV related cognitive impairment, frontotemporal lobar degeneration, hypothyroidism, Lewy body dementia, Parkinson's disease, prion disease, syphilis, traumatic brain injury, vitamin B12 deficiency)
  - ❑ History of significant cardiac disease (e.g., chronic heart failure, clinically significant conduction abnormalities, history of unstable angina, myocardial infarction, uncontrolled hypertension) within past one year
  - ❑ Impaired renal or liver function
  - ❑ Relevant brain hemorrhage, bleeding disorder, or cerebrovascular abnormalities
  - ❑ Use of antiplatelet or anticoagulant medications other than prophylactic aspirin, including warfarin, DOACs, and $P2Y_{12}$ inhibitors
- ❑ The requested dose follows FDA prescribing information

Re-authorization Criteria:

- ❑ Absence of amyloid-related imaging abnormalities with edema (ARIA-E) or hemosiderin deposition (ARIA-H) before the 4th, 7th, and 12th infusions as determined by brain MRI
- ❑ Continued evidence of mild cognitive impairment as evidenced by an updated CDR global scale score ≤0.5, RBANS delayed memory index score ≤85, and MMSE score ≥24
- ❑ Titration up to 10 mg/kg maintenance dose

Initial Authorization: Up to six (6) months
Re-authorization: 6 months

PROVIDER CERTIFICATION

I hereby certify this treatment is indicated, necessary and meets the guidelines for use.

_____ _____

Prescriber's Signature Date